A Risk-Benefit Assessment of Tamoxifen Therapy
- 1 May 1993
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 8 (5) , 381-397
- https://doi.org/10.2165/00002018-199308050-00005
Abstract
Tamoxifen is the endocrine treatment of choice for all women with hormonally responsive breast cancer. 30 years of experience in both the laboratory and clinical setting have shown tamoxifen to be an...Keywords
This publication has 99 references indexed in Scilit:
- Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifenJournal of Hepatology, 1990
- A controlled study of the ocular effects of tamoxifen in conventional dosage in the treatment of breast carcinomaEuropean Journal of Cancer and Clinical Oncology, 1989
- A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive TumorsNew England Journal of Medicine, 1989
- Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: A model to study the tumoristatic action of tamoxifenJournal of Steroid Biochemistry, 1988
- Adjuvant tamoxifen in primary breast cancer: Influence on plasma lipids and antithrombin III levelsBreast Cancer Research and Treatment, 1988
- Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two yearsBreast Cancer Research and Treatment, 1988
- Effect of tamoxifen on oestrogen binding, lipid and lipoprotein concentrations and blood clotting parameters in premenopausal women with breast painJournal of Endocrinology, 1988
- Tamoxifen and progesterone effects in target tissues during the perinatal periodJournal of Steroid Biochemistry, 1986
- Tamoxifen in advanced breast cancerCancer Treatment Reviews, 1978
- Oestrogen-responsive human breast cancer in long term tissue cultureNature, 1975